At what enterprise value was LABEXA acquired in 2021?

During the acquisition of LABEXA by CERBA HEALTHCARE in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LABEXA when it was acquired by CERBA HEALTHCARE?

The estimated EV/EBITDA multiple for LABEXA is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was LABEXA acquired by CERBA HEALTHCARE?

LABEXA was acquired by CERBA HEALTHCARE in 2021.

What was the revenue of LABEXA at the time of the deal?

The revenue of LABEXA at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LABEXA during the acquisition?

LABEXA's EBITDA is estimated to be in the range of 25M - 50M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LABEXA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABEXA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/build-up/cerba-officialise-lacquisition-de-labexa-1365891

← DATABASE

Home Database Healthcare & PharmaLABEXA

11/2021

LABEXA acquired by CERBA HEALTHCARE

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV 300M - 700M EUR

Context

Cerba HealthCare acquired Labexa following a competitive auction process managed by Oddo BHF, beating out its main rival Biogroup. The acquisition allows Cerba to significantly strengthen its footprint in the French "Nouvelle-Aquitaine" region. The transaction followed Cerba's massive EUR1.2 billion acquisition of Lifebrain in Italy and was finalized shortly after Cerba's own LBO with EQT. The target's biologist-partners opted for an industrial exit to join a major laboratory network.

By taking control of Labexa, Cerba Healthcare continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Lifebrain in 2021.

LABEXA, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Labexa is a leading medical biology group in the Nouvelle-Aquitaine region, formed through the successive merger of several networks (Exalab, LBA, Sealab, and Accolab Sud-Ouest). It operates 94 sites with 1,000 employees across seven departments in southwestern France. In 2020, the group generated approximately EUR120 million in revenue.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
12/2021	VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT	VIVALTO SANTÉ	FRANCE	Health Providers	Vivalto Santé completed its third LBO, with Vivalto Partners — Daniel Caille's newly created investment management vehicle — taking control of the group. IK Partners joined as a key new minority shareholder alongside a broad consortium of reinvesting French institutional investors and the Bpifrance-Mubadala sovereign duo
12/2021	RAMSAY HEALTH CARE	ELYSIUM HEALTHCARE	UNITED KINGDOM	Health Providers	Ramsay Health Care entered into a definitive agreement on December 13, 2021, to acquire 100% of the UK-based mental healthcare provider Elysium Healthcare from BC Partners to solidify its standing within the specialized British clinical landscape
10/2021	ARES / BPIFRANCE	POINT VISION	FRANCE	Health Providers	Ares Management acquired a majority stake in Point Vision following a highly competitive auction process (beating Adagia, Ramsay, and Elsan). Bpifrance joined as a minority shareholder alongside Ares and the three founders who reinvested
10/2021	IVC EVIDENSIA	VETONE	FRANCE	Health Providers	IVC Evidensia acquired VetOne in a preemptive move to consolidate its leadership in the French market. The deal successfully bypassed a planned auction process due to a high-premium offer. The transaction provided an exit for VetOne's shareholders, including the founder, practicing veterinarians, and various private investors
10/2021	THE CRANEMERE GROUP	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Health Providers	Cranemere Group has acquired a majority stake in Outpatient Imaging Affiliates (OIA), a leading US provider of outpatient medical imaging services. This transaction strengthens Cranemere's presence in the healthcare sector by partnering with a prominent player in the diagnostic imaging market
09/2021	LIVINGBRIDGE	EVERLIGHT RADIOLOGY	UNITED KINGDOM	Health Providers	Livingbridge has announced the acquisition of a stake in Everlight Radiology, a world-renowned teleradiology provider, from Intermediate Capital Group (ICG), a global alternative asset manager. This secondary LBO transaction provides the technology-enabled healthcare platform with a new premier institutional sponsor to back its next international growth chapter
08/2021	COLOSSEUM DENTAL GROUP	CURAEOS	NETHERLANDS	Health Providers	Colosseum Dental Group (CDG), a subsidiary of the Swiss-based Jacobs Holding, has successfully entered into a definitive agreement to acquire 100% of Curaeos. This transaction represents a transformative milestone in the group’s expansion strategy, creating the premier global dental services platform with approximately 800 clinics and over 13,000 professionals
07/2021	EQT PARTNERS	BLIKK GROUP	GERMANY	Health Providers	The acquisition of Blikk Group by EQT Infrastructure, occurring simultaneously with the buyout of Meine Radiologie Holding from Triton, is a landmark consolidation in the German healthcare services market
07/2021	EQT PARTNERS	MEINE RADIOLOGIE	GERMANY	Health Providers	The acquisition of Meine Radiologie Holding by EQT Infrastructure from Triton is a cornerstone transaction in the consolidation of the German outpatient imaging market. Occurring simultaneously with EQT’s acquisition of the Blikk Group from DBAG, the primary rationale for the deal is the merger of these two established entities into a single, market-leading radiology platform
07/2021	OMERS	AMEDES	GERMANY	Health Providers	A consortium led by Goldman Sachs Asset Management and OMERS Infrastructure acquired amedes from Antin Infrastructure Partners. The transaction valued roughly doubling its value since Antin's entry in 2015

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABEXA by CERBA HEALTHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: cerba healthcare